natgillin/translations-raw huggingface dataset:
The invention is further defined by reference to the following examples describing in detail the preparation of the composition and methods of use of the invention. 
Izum je dalje definiran s obzirom na sljedeće primjere koji detaljno opisuju pripremu smjese i metode uporabe izuma.
Fractioning with urea and molecular distillation are the techniques, pointed out in the above mentioned monograph, for compositions based on EPA ethyl ester, DHA ethyl ester and other minor components of the w-3 series. 
Frakcioniranje s ureom i molekularna destilacija su tehnike, istaknute u gore spomenutoj monografiji, za pripravke na bazi EPA etil estera, DHA etil estera i drugih manje prisutnih spojeva -3 serije.
In powders, the carrier is a finely divided solid that is in admixture with the finely divided active ingredient. 
U prahu, nosač je fino razdijeljena krutina koja je u smjesi s fino razdijeljenim aktivnim sastojkom.
freezing and/or deep-freezing the raw food in said arch or multiple arch shape, 
(v) zamrzavanje i / ili duboko zamrzavanje sirovog prehrambenog proizvoda u obliku navedenog luka ili višestrukih lukova,
extracting, from a data stream, a significance map indicating positions of significant transform coefficients within the transform coefficient block, and the significant transform coefficients within the transform coefficient block; 
Postupak za kodiranje signifikacijske mape u protok podataka, koja prikazuje pozicije signifikantnih koeficijenata transformacije unutar bloka koeficijenata transformacije, naznačen time, da taj postupak obuhvaća sljedeće:
The curing reaction takes place by the reaction of unsaturated cycloalkenyl groups. 
Reakcija otvrdnjavanja se odvija preko reakcije nezasićenih cikloalkenilnih skupina.
is prepared by the following step A1 wherein a compound of formula (1): optionally in solution in a solvent, such as dichloromethane for example, is allowed to react with nitric acid and sulphuric acid, and then 
HR P20190527 T1 priprema slijedećim korakom A1: pri čemu je spoj s formulom (1): a) = ostavljen da reagira s dušičnom kiselinom i sumpornom kiselinom, te zatim slijedi b) - dodavanje baze, čime se dobiva spoj s formulom (2).
A further aspect of the present invention relates to a method of treating plants, including transgenic plants, in need of better growth, increased harvest yields, a better developed root system, a larger leaf area, greener leaves and/or stronger shoots comprising applying to said plants active compound combinations or fungicidal compositions according to the present invention. 
Postupak prema zahtjevu 5, naznačen time što je poboljšani rast naznačen time što ima barem jedan od učinaka iz skupine koja se sastoji od boljeg rasta, povećanih prinosa žetve, bolje razvijenog korijenskog sustava, veće površine listova, zelenijih listova i jačih izbojaka.
Preferably, the position information-deriving unit is operable, when the second positioning signal transmitted by the indoor transmitter which is one of a plurality of indoor transmitters, is received, to acquire the position data from the signal obtained by the demodulation, and, when a plurality of the first positioning signals are received, to calculate the position information based on respective spread spectrum signals of the plurality of received first positioning signals. 
Sustav za pružanje informacija o položaju prema zahtjevu 1, naznačen time što je jedinica za deriviranje podataka o položaju podešena tako da bi po prijemu drugog pozicijskog signala koga prenosi jedan od više unutrašnjih odašiljača, prikupila podatke o položaju iz signala dobivenog demodulacijom, i po prijemu više prvih pozicijskih signala, izračuna položajne informacije na osnovu odgovarajućih signala raspršenog spektra iz primljenog mnoštva pozicijskih signala.
Although accelerated conditions (50°C) were used for stability testing and tablets were not packaged in contact packing material, e.g. blisters, donepezil hydrochloride hydrate remained unchanged. 
Iako su za ispitivanje stabilnosti korišteni pojačani uvjeti (50 *C) i tablete nisu bile pakirane u kontaktu sa materijalom za pakiranje, primjerice blisterima, donepezil hidroklorid hidrat je ostao nepromijenjen.
a bispecific antibody (Q499-z121/J339-z119/L377-k), wherein the first polypeptide is an H chain consisting of the amino acid sequence of SEQ ID NO: 20, the second polypeptide is an H chain consisting of the amino acid sequence of SEQ ID NO: 26, and the third polypeptide and the fourth polypeptide are a commonly shared L chain of SEQ ID NO: 31; and 
bispecifično protutijelo, gdje prvi polipeptid je H-lanac koji se sastoji od aminokiselinske sekvence od SEQ ID NO: 20, drugi polipeptid je H-lanac koji se sastoji od aminokiselinske sekvence od SEQ ID NO: 26, a treći polipeptid i četvrti polipeptid su zajednički korišten L-lanac od SEQ ID NO: 31; i
In another embodiment, an antikine will bind to at least two or three of CCL3/MIP-1a, CCL4/MIP-1B, CCL5/RANTES, and CCL2/MCP-1 which interact with CCR1, CCR2 and CCR5. 
Monoklonsko protutijelo, ili njegov fragment koji veže antigen, u skladu s patentnim zahtjevom 1, naznačeno time, da se veže na najmanje jednu determinantu CCL2/MCP-1, CCL3/MIP-10, CCL4/MIP- 18, CCLS/RANTES,
A sealed container according to any of embodiments 10 to 14, wherein the thickness of the lidding film is from 20 µm to 60 µm. 
Posuda prema bilo kojem od patentnih zahtjeva 10 do 13, pri čemu je debljina tankog filma od 20 um do 60 um.
The immunogenic composition of any one of claims 3-6 wherein the at least two further bacterial saccharide conjugates comprise N. meningitidis serogroup W135 capsular saccharide (MenW). The immunogenic composition of any preceding claim comprising a N. meningitidis serogroup B outer membrane vesicle preparation. The immunogenic composition of any preceding claim wherein the at least two further bacterial saccharide conjugates comprise a S. pneumoniae capsular saccharide derived from a strain selected from the group consisting of serotypes 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F and 33F. 
Postupak u skladu s patentnim zahtjevima 1-6, naznačen time što je saharid saharid iz bakterijske kapsule, primjerice dobiven iz bakterije koju se bira sa spiska kojeg čine: N. meningitidis seroskupina A, B, C, W135 ili Y, Streptococcus pneumoniae serotipovi 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F ili 33F, Group B Streptococcus skupina la, Ib, II, III, IV, V, VI ili VII, Staphilococcus aureus tip 5, Staphilococcus aureus tip 8, Salmonella typhi (saharid Vi), Vibrio cholerae, ili H. influenzae tip b.
An agent for use according to claim 1 wherein the pharmaceutically acceptable excipients and/or carriers are additionally selected from at least one coemulsifying agent, which includes oxyethylenated sorbitan monostearate, fatty alcohols, such as stearyl alcohol or cetyl alcohol, or esters of fatty acids and polyols, such as glyceryl stearate. 
Sredstvo sukladno patentnom zahtjevu i, naznačeno time, da farmaceutski prihvatljivi ekscipijenti 1 / ili nosači dodatno biraju iz barem jednog koemulzijskog sredstva koje uključuju oksietilenirani sorbitan monostearat, masne alkobole kao stearilni alkohol ili cetilni alkohol, ili estere masnih kiselina i poliole kao što je gliceril stearat.
The formulation of claim 1, wherein the AMG 416 is present in the formulation at a concentration of 1 mg/mL to 15 mg/mL. 
Formulacija iz patentnog zahtjeva 1, pri čemu je AMG 416 prisutan u formulaciji u koncentraciji od 1 mg/mL do 15 mg/mL.
The present invention will now be further illustrated with reference to Examples and a Figure. 
Ovaj izum će u nastavku biti podrobnije opisan kroz Primjere i Sliku.
a torque is imparted on the propulsive element at two distinct points (Pa, Pb) which are rigidly connected to the frame, 
se okretni moment prenosi na propulzivni element u dvjema zasebnim točkama (Pa, Pb) koje su čvrsto povezane s okvirom
The receiver according to claim 1, wherein the sponge is constructed of cellulose or other absorbent material. 
Prijemna posuda sukladno patentnom zahtjevu 8 naznačena time što je spužva napravljena od celuloze ili drugog apsorbirajućeg materijala.
The apparatus according to claim 9, wherein preserving the predetermined amount of fluid within the piston seat cavity volume determines a piston seat cover height relative to the first piston part. 
Uređaj u skladu s patentnim zahtjevom 1, naznačen time da očuvanje prethodno određene količine fluida unutar volumena šupljine sjedišta klipa određuje visinu poklopca sjedišta klipa u odnosu na prvi dio klipa.
wherein the Big Brother (BB) polypeptide comprises an amino acid sequence having at least 50% sequence identity to SEQ ID NO: 9 and has E3 ubiquitin ligase activity. 
Postupak prema zahtjevu 3, naznačen time, da nadalje obuhvaća smanjenje ili poništenje ekspresije polipeptida Big Brother (BB), u stanicama navedene biljke, pri čemu polipeptid Big Brother (BB) obuhvaća aminokiselinsku sekvencu koja ima najmanje 50% identiteta sekvence od SEQ ID NQO:9, te ima aktivnost ligaze £3-ubikvitina.
or a compound of the formula (I-1) is hydrolysed in an inert solvent in the presence of a suitable acid or base to give a compound of the formula (I-2) 
[D] spoj s formulom (I-1) hidrolizira u inertnom otapalu u prisutnosti odgovarajuće kiseline ili baze da se dobije spoj s formulom (I-2)
“ ” is point of attachment; 
s je točka vezivanja;
Compared to oligofructose, resistant maltodextrin offers the advantage that there is no sudden and excessive fermentation in the large intestine that can cause flatulence, abdominal pain and/or diarrhoea. 
U usporedbi s oligofruktozom, prednost je rezistentnog maltodekstrina što nema njegove iznenadne ni opsežne fermentacije u debelom crijevu, koja bi mogla izazvati nadutost, bol u trbuhu i/ili proljev.
The wave-power unit according to claim 5, wherein said resilient material consists of rubber. The wave-power unit according to claim 4, wherein the flexible member is coaxial with the rod and has at least one portion that is of convex shape in the longitudinal direction in unloaded state when seen from the outside. 
Jedinica pogonjena energijom valova u skladu s patentnim zahtjevom 4 i 5, naznačena time što je fleksibilni element (15) koaksijalan sa štapom (7) i ima najmanje jedan dio (20) konveksnog oblika u uzdužnom smjeru u nenapunjenom stanju kada se gleda izvana.
with the proviso that the sum of i+j is 2, 3 or 4. 
pod uvjetom da zbroj i+j iznosi 2, 3 ili 4.
The system of claim 19, wherein the triggering control and switch systems are further configured to enable magnetic compression of the compact toroid by active magnetic coils in a staged sequence following the staged sequence of compact toroid formation and axial acceleration by active magnetic coils. 
Sustav (100, 200) prema zahtjevu 5, naznačen time, da su otponski kontrolni i sklopni sustavi (120) dalje konfigurirani za omogućavanje magnetske kompresije kompaktnog torusa pomoću aktivnih magnetskih zavojnica (32N, 32S, 36N, 36S) u naslaganom nizu slijedom nakon naslaganog niza tvorbe kompaktnog torusa te za aksijalno ubrzavanje pomoću aktivnih magnetskih zavojnica (32N, 32S, 36N, 36S).
There have been few attempts to model the cognitive disturbances in schizophrenia, although some of the more recent, and arguably more valid animal models show cognitive deficits. The classical approaches used to provide animal models for the testing of potential antipsychotics have relied on the use of dopaminergic drugs, the limitations of which are increasingly being recognised. 
Bilo je nekoliko pokušaja određivanja modela kognitivnih poremećaja u šizofreniji, premda neki noviji i dokazivo ispitivanje snažnih antipsihotika su se zasnivali na uporabi dopaminergičnih lijekova, čija ograničenja postaju sve prepoznatljivija.
The drug injection device of claim 1, wherein the drug syringe mounting component is a sledge to which the drug syringe can be removably attached. A drug injection device of claim 1, wherein the drive mechanism comprises a drive for the piston and another drive for the drug syringe mounting component. 
Uređaj za injektiranje lijeka prema zahtjevu 1 ili 2, naznačen time što komponenta za postavljanje štrcaljke za lijek su sanjke (13) na koje se može odvojivo pričvrstiti štrcaljka za lijek (17).
The process according to claim 3 wherein the mechanical particle size reduction is performed by wet milling. 
Postupak prema zahijevu 3 naznačen time da se mehaničko smanjenje veličine čestica provodi vlažnim mljevenjem.
A process for preparing a crystalline form C of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide methanesulfonate as defined in claim 1, comprising a step of heating a crystalline form of the dimethyl sulfoxide solvate of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide methanesulfonate. 
Postupak za pripravu kristalnog oblika C od 4-(3-kloro-4-(ciklopropilaminokarbonil)aminofenoksi)-7-metoksi-6- kinolinkarboksamid metansulfonata, kako je definirano u zahtjevu 1, naznačen time, da sadrži korak grijanja kristalnog oblika solvata dimetil sulfoksida od 4-(3-kloro-4-(ciklopropilaminokarbonil)aminofenoksi)-7-metoksi-6- kinolinkarboksamid metansulfonata.
Statement 53. The method of statement 52, wherein the disease or condition is selected from asthma, COPD, exacerbation of airways hyper reactivity consequent to other drug therapy, allergic rhinitis, sinusitis, pulmonary vasoconstriction, inflammation, allergies, impeded respiration, respiratory distress syndrome, pulmonary hypertension, pulmonary vasoconstriction, and pulmonary inflammation and obstruction associated with cystic fibrosis. 
Ko-suspenzija namijenjena upotrebi u skladu s patentnim zahtjevom 20, naznačena time što se plućna bolest ili poremećaj bira između najmanje jednog od astme, COPD, pogoršanja preosjetljivosti dišnih puteva kao posljedice terapije drugim lijekom, alergijskog rinitisa, sinusitisa, plućne vazokonstrikcije, upale, alergija, otežanog disanja, respiratornog distresnog sindroma, plućne hipertenzije, te upale pluća i opstrukcije povezane s cističnom fibrozom.
The layer sequence of the arrangement 1, which is shown in Figures 2b and 2c, corresponds to the layer sequence of the overall plate-shaped composite structure which was present at the start of this manufacturing step (see Figure 3). 
Slojeviti dio naprave 1, koji je prikazan na slikama 2b i 2c, odgovara slojevitom dijelu ukupne pločaste kompozitne strukture koja je postojala na početku ovog stupnja proizvodnje (vidi sliku 3).
A method according to Item 1 wherein the temperature is set at 36.5 °C. A method of culturing heterologous protein-secreting mammalian cells in a cell culture supernatant wherein the cell culture supernatant is maintained at a pH that is set at X±0.05 wherein X has a value of from 7.15 to 7.20, with the proviso that the pH is set at greater than 7.10. 
Postupak uzgoja sisavačkih stanica koje izlučuju heterologni protein u supernatantu kulture stanica, naznačen time što se supernatant kulture stanica održava na pH podešenom na X + 0,05, gdje X ima vrijednost od 7,15 do 7,20, uz uvjet da je pH podešen na vrijednost veću od 7,10, gdje je kultura stanica kontinuirana kultura koju se održava uz gustoću od 1,4 x 105 do 2,8 x 105 stanica/ml.
Synthesis of analogues where Y=CONH begins with either alkylation of the appropriately substituted 2-nitro-aniline or addition of a substituted amine to the appropriately substituted 2-fluoro-nitrobenzene. 
Sinteza analoga, gdje je Y=CONH, počinje ili s alkilacijom odgovarajućeg supstituiranog 2-nitro-anilina ili adicijom supstituiranog amina odgovarajuće supstituiranom 2-fluor-nitrobenzenu.
fermentation of the hydrolysed lignocellulosic material to produce a fermentation product, and 
fermentaciju hidroliziranog lignoceluloznog materijala radi dobivanja fermentacijskog proizvoda, i
and G have the same meaning as in formula I; 
A4 1 G imaju isto značenje kao u formuli I;
(f2B) computing a normalization factor for each peptide and sample using said mean presentation value as calculated in step(f2a); and 
(128) izračunavanje normalizacijskog čimbenika za svaki peptid i uzorak uporabom navedene prezentacijske vrijednosti izračunate u koraku (124);
Alternatively, the neutral form of the compound can be prepared by crystallization of the above-described salts in an organic solvent or a mixture of an organic solvent and water in the presence of a small amount of an acid. Any suitable acid can be used. 
Cc) - pročišćavanje soli spoja s formulom (V), kristalizacijom soli spoja s formulom (V) u organskom otapalu ili smjesi organskog otapala i vode u prisutnosti kiseline, da se dobije neutralni oblik spoja s formulom (V).
The ophthalmic solution according to any of the preceding Claims, wherein the N-(N-acetylcysteinyl-)chitosan used for the preparation of the solution exhibits at a concentration of 0.5% in water at 25°C a kinematic viscosity within the range of 1 to 15 mm2/s, preferably 2 to 10 mm2/s. 
Oftalmološka otopina prema bilo kojem od prethodnih zahtjeva, naznačena time da N-(N-acetilcisteinil-)kitozan korišten za pripremu otopine ima pri koncentraciji od 0,5% u vodi na 25 *C kinematski viskozitet unutar raspona od 1 do 15 mm'/s, poželjno 2 do 10 mm//s.
Waterproofing membrane based on bitumen modified with polymers containing hollow glass microspheres. 
VODOOTPORNE MEMBRANE TEMELJENE NA BITUMENU MODIFICIRANOM POLIMERIMA KOJI SADRŽE ŠUPLJE STAKLENE MIKROSFERE
A hydrogen sulfate salt of Compound 1: 
Sol hidrogen sulfata od Spoja 1. o
As the hot water outlet is common to more than one thermoblock, the invention thus goes beyond a simple aggregation of several independent and parallel systems. 
Kako je izlaz za vruću vodu zajednički za više termoblokova, ovaj izum je više od pukog sklopa nekoliko neovisnih i paralelnih sustava.
A pharmaceutical composition comprising the compound of claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent or excipient. 
Farmaceutski preparat koji sadrži spoj prema patentnom zahtjevu 1, ili njegovu farmaceutski prihvatljivu sol, i farmaceutski prihvatljiv nosač, razblaživač ili ekscipijens.
providing mammalian cells, wherein the cells comprise a first expression vector and a second expression vector; and 
(a) pružanje stanica sisavca, pri čemu stanice sadrže prvi ekspresijski vektor i drugi ekspresijski vektor; i
A di(C 1-6 alkyl)amino group includes independently selected alkyl groups, to form, for example, methylpropylamino and isopropylmethylamino, in addition dialkylamino groups having two of the same alkyl group such as dimethyl amino or diethylamino. 
Di(C;.4 alkil)amino skupina uključuje neovisno odabrane alkilne skupine, koje tvore na primjer metilpropilamino i izopropilmetilamino, te nadalje dialkilamino skupine koje imaju dvije iste alkilne skupine kao što su dimetilamino ili dietilamino.
or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a polymorph, a solvate or a hydrate thereof, wherein: ring A is independently a 5- to 6-membered heteroaryl comprising carbon atoms and 1-4 heteroatoms selected from N, NRe, O and S; wherein said heteroaryl is substituted with 0-1 R6 and 0-2 R7; 
(I) ili stereoizomer, tautomer, farmaceutski prihvatljiva sol, polimorf, solvat ili hidrat tog spoja, gdje: prsten A je nezavisno 5- do 6-očlani heteroaril koji sadrži ugljikove atome i 1-4 heteroatoma odabrana od N, NR", O i S; gdje spomenuti heteroaril je supstituiran sa 0-1 R*10-2R';
The method of either of claims 1 or 2, wherein the biological sample is serum. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što je biološki uzorak serum.
An agent according to claim 13 for use in the treatment and/or prevention of a disease involving abnormal bone resorption. 
Sredstvo prema zahtjevu 6, za primjenu u liječenju i/ili sprječavanju reumatoidnog artritisa.
The offshore aquaculture method of claim 11, further comprising removing biofouling from the framework mechanically upon moving the cages. 
Sustav odobalne akvakulture prema zahtjevu 11, koji uključuje mehaničko odstranjivanje bioobraslina iz okvira nakon pomicanja rešetki.
Figure 2b shows that the engraved design of the magnetic plate has been transferred with high resolution into the magnetic optically variable ink patch; this latter shows some kind of 3-dimensional effect and a seems to move when the print is looked at from different angles. 
Slika 26 prikazuje kako je ugravirani uzorak u visokoj rezoluciji prenesen s magnetske ploče na otisak magnetske optički varijabilne tinte; potonju odlikuje 3-dimenzionalni učinak, a kada se otisak gleda 1z različitih kuteva čini se kako se kreće.
and wherein any atom of the ring structure of the 5-7 membered carbocycle or heterocycle is optionally substituted in one or more positions with R9; 
[image] i pritom je bilo koji atom iz prstenaste strukture od 5-7-članog karbocikla ili heterocikla, opcionalno supstituiran na jednoj ili više pozicija s R9;
Spheroids according to claim 13, wherein the water soluble celluloses comprise hydroxypropylmethyl cellulose and hydroxypropyl cellulose. 
Sferoidi prema bilo kom od patentnih zahtjeva 16 do 19 naznačeni time što celuloze rastvorljive u vodi sadrže hidroksipropilmetil celulozu i hidroksipropil celulozu.
The compound of Paragraph 40, wherein X42 is N. 
Spoj prema zahtjevu 34, pri čemu X42 je N.
Clause 23. The antisense oligonucleotide of clause 22, wherein the non-natural inter-nucleotide linkages are modified phosphates. 
Antisens oligonukleotid u skladu sa zahtjevom 8, naznačen time što neprirodne internukleotidne veze su modificirani fosfati.
A maintenance period wherein Cladribine is administered and wherein the total dose of Cladribine administered during the maintenance period is lower than or equal to the total dose of Cladribine reached at the end of the induction period (i); 
(11) period održavanja pri čemu da se primjenjuje Kladribin i pri čemu ukupna doza Kladribina koja se daje tijekom perioda održavanja je niža od ili jednaka ukupnoj dozi Kladribina dosegnutoj na završetku perioda indukcije (1);
and R16 together with the nitrogen to which they are attached form morpholinyl, piperazinyl, or piperazinyl substituted with C1-6alkyloxycarbonyl. 
Ri R'* zajedno sa dušikom na koji su spojeni tvore morfolinil, piperazinil, ili piperazinil supstituiran sa C). salkiloksikarbonilom.
The composition for use according to claim 23, wherein the therapeutically effective amount of the composition is provided in an amount that decreases a subject bone marrow blast count. 
Pripravak namijenjen uporabi u skladu s patentnim zahtjevom 23, pri čemu je terapeutski djelotvorna količina pripravka osigurana u količini koja smanjuje broj blasta koštane srži.
supplying injection material to the auxiliary injection line (25) on one side of the assembly (3), 
- < dovođenje injekcijskog materijala do pomoćne injekcijske linije (25) na jednoj strani sklopa (3),
0060674, and others can be prepared analogously. 
0060674, a drugi se mogu načiniti na analogan način.
Process according to Claim 7, wherein the water-soluble silicate compound is sodium metasilicate, potassium metasilicate and/or waterglass. 
Uporaba prema patentnom zahtjevu 6, naznačena time da je silikatni spoj topiv u vodi izabran od natrij metasilikata, kalij metasilikata i/ili natrij silikata.
Use of Claim 56 or 73, wherein the AOID is uveitis. 
Uporaba u skladu sa zahtjevom 56 ili 73, naznačena time, da AQID je uveitis.
The compound of claim 2, wherein the cancer is selected from breast cancer, colon cancer, lung cancer, melanoma, prostate cancer, and renal cancer. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što se rak bira između raka dojke, raka debelog crijeva, raka pluća, melanoma, raka, te raka bubrega.
After another 20 hours stirring, the precipitate was filtered via Buchnner funnel and the yellow solid was washed with water and EtOAc to give 1c as a white solid (48.5 g, 16 mmol). 
Nakon još 20 sati miješanja talog se filtrira kroz Biichnnerov lijevak, a žutu krutinu ispere vodom i s EtOAc kako bi se dobilo 1e u obliku bijele krutine (48,5 g, 16 mmol).